CHEAPEST GROWTH IN S&P. 0.8 PEG vs AMGN/BIIB 1.2/1.1. 2016 PEG is CRAZY 0.4
It is indeed true that Celgene despite the recent run up is dirt cheap vs AMGN and BIIB - has a MUCH better pipeline and growth rate than both of those and is still at a DEEP DEEP disount from a PE to EPS growth perspective.
I see this $110 quickly after earnings call and Abraxane Ph 3 Panc ca survival data this week. Add another $3 - $5 when Pomalyst is approved in the next 2 weeks and then if MM020 is great - you can add another $15 over the following week or so.